Project Grant R43GM136013

This $306,656 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on approaches to enable large-scale biomanufacturing of heparin, a critical anticoagulant medication. The award was granted to Bioparin, LLC on February 1, 2025, with a planned completion date of January 31, 2026. The project aims to develop alternative, reliable modern drug production processes for heparin,...

This $360,320 Project Grant awarded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) aims to develop and test the first continuous electrochemical sensors for monitoring large protein and peptide analytes, such as insulin and cardiac markers. The project, titled "Aptamer Tagging with Redox Quenchers: A Critical Breakthrough in the Sensitivity of...

Novelmed Therapeutics, Inc. was awarded a $1,599,495 Project Grant from the National Heart, Lung and Blood Institute of the Department of Health and Human Services. The grant falls under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. Novelmed will use the funding to develop a novel disease-modifying treatment for paroxysmal nocturnal hemoglobinuria (PNH). The company's lead drug candidate selectively inhibits the alternative pathway of...

This Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) provides $379,730 to the University of North Carolina at Chapel Hill to develop a continuous electrochemical sensor for monitoring therapeutic monoclonal antibodies, using the FDA-approved drug bevacizumab as an example. The research aims to overcome challenges in discriminating between therapeutic antibodies and human IgG in biological fluids, and in regenerating the aptamer binding site for...

The National Science Foundation Division of Chemistry awarded The Johns Hopkins University a three-year Project Grant totaling $575,000 under the Mathematical and Physical Sciences federal grant program (CFDA 47.049). The grant supports research into the generation and reactivity of biologically relevant reactive sulfur species, including hydroperoxides, and the development of novel photoprecursors and protein persulfidating reagents to produce these species. Professor John P. Toscano of Johns...

This federal Project Grant award of $542,442.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support the development and testing of a new molecular sensor, named MCATS (Mechano-Assisted CAS12A Tension Sensor), that can detect the mechanical forces generated by human platelets. This technology aims to provide rapid and accurate diagnosis of Heparin-Induced Thrombocytopenia (HIT), which is a serious condition affecting a small percentage of...

The National Institute of General Medical Sciences (NIGMS) awarded a $413,036 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Arizona State University (ASU) to develop a new single-molecule sequencing method for glycosaminoglycans (GAGs) using fluorophore-labeled lysosomal GAG degradation enzymes. GAGs are a family of complex polysaccharides with diverse biological functions, but their analysis has been challenging due to their size, complexity, and...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, provides $350,000 to Exhalix, LLC to develop the GENIE:S on-demand sulfide synthesis and delivery platform technology for treating peripheral artery disease (PAD) and chronic limb-threatening ischemia (CLTI). The award period runs from September 16, 2025 to September 15, 2026. The GENIE:S platform aims to enable targeted, precision delivery of hydrogen sulfide (H2S) to ischemic...

Partillion Bioscience Corp. was awarded a $659,037 Project Grant from the National Institutes of Health's National Institute of General Medical Sciences to develop reagent products enabling high-throughput screening and selection of single cells based on secreted bio-products. Under the Biomedical Research and Research Training program (CFDA 93.859), Partillion plans to transition its lab-on-a-particle technology—highlighted as a 2020 SLAS Innovation Award winner—into the first reagent product...

The federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), part of the 93.350 CFDA program, will support the development of a novel biosensor for the detection of bacterial endotoxins. Through this $290,066 award, the awardee Monod Bio, Inc. will focus on (I) computational design and experimental selection of functional lipopolysaccharide (LPS) bioluminescent biosensors, (II) in vitro evolution of these biosensors to optimize sensitivity and stability,...